Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as Potent α4β2 nicotinic acetylcholine receptor ligands

Journal of Medicinal Chemistry

Volumn 54, Issue 21, 2011, Pages 7678-7692

  Scanio, Marc J C ^a   Shi, Lei ^a   Bunnelle, William H ^a   Anderson, David J ^a   Helfrich, Rosalind J ^a   Malysz, John ^a   Thorin Hagene, Kirsten K ^a   Van Handel, Ceclia E ^a   Marsh, Kennan C ^a   Lee, Chih Hung ^a   Gopalakrishnan, Murali ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [HEXAHYDROPYRROLO[3,4 C]PYRROL 2(1H) YL] N (2 METHYLBENZYL)PYRAZINE 2 CARBOXAMIDE; AMIDE; AZABICYCLO DERIVATIVE; LIGAND; NICOTINIC RECEPTOR ALPHA4BETA2; OCTANE; POZANICLINE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; LIGAND BINDING; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; CELL LINE, TUMOR; DRUG PARTIAL AGONISM; HEK293 CELLS; HUMANS; LIGANDS; NEURONS; NICOTINIC AGONISTS; PYRAZINES; PYRIDINES; PYRROLIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, NICOTINIC; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80455140509     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201045m     Document Type: Article

References (72)

1. D'Hoedt, D.; Bertrand, D. Nicotinic acetylcholine receptors: an overview on drug discovery Expert Opin. Ther. Targets 2009, 13, 395-411
2. Arneric, S. P.; Holladay, M.; Williams, M. Neuronal nicotinic receptors: A perspective on two decades of drug discovery research Biochem. Pharmacol. 2007, 74, 1092-1101
3. Langmead, C. J.; Watson, J.; Reavill, C. Muscarinic acetylcholine receptors as CNS drug targets Pharmacol. Ther. 2008, 117, 232-243
4. Gregory, K. J.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of muscarinic acetylcholine receptors Curr. Neuropharmacol. 2007, 5, 157-167
5. Wess, J. Muscarinic acetylcholine receptors Handb. Contemp. Neuropharmacol. 2007, 1, 147-192
6. Ishii, M.; Kurachi, Y. Muscarinic acetylcholine receptors Curr. Pharm. Des. 2006, 12, 3573-3581
7. Lloyd, G. K.; Williams, M. Neuronal nicotinic acetylcholine receptors as novel drug targets J. Pharmacol. Exp. Ther. 2000, 292, 461-467
8. Newhouse, P. A.; Potter, A.; Kelton, M.; Corwin, J. Nicotinic treatment of Alzheimer's disease Biol. Psychiatry 2001, 49, 268-278
9. Bunnelle, W. H.; Daanen, J. F.; Ryther, K. B.; Schrimpf, M. R.; Dart, M. J.; Gelain, A.; Meyer, M. D.; Frost, J. M.; Anderson, D. J.; Buckley, M.; Curzon, P.; Cao, Y.-J.; Puttfarcken, P.; Searle, X.; Ji, J.; Putman, C. B.; Surowy, C.; Toma, L.; Barlocco, D. Structure-Activity Studies and Analgesic Efficacy of N -(3-Pyridinyl)-Bridged Bicyclic Diamines, Exceptionally Potent Agonists at Nicotinic Acetylcholine Receptors J. Med. Chem. 2007, 50, 3627-3644
10. Adler, L. E.; Olincy, A.; Waldo, M.; Harris, J. G.; Griffith, J.; Stevens, K.; Flach, K.; Nagamoto, H.; Bickford, P.; Leonard, S.; Freedman, R. Schizophrenia, sensory gating, and nicotinic receptors Schizophrenia Bull. 1998, 24, 189-202
11. Potter, A.; Corwin, J.; Lang, J.; Piasecki, M.; Lenox, R.; Newhouse, P. A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease Psychopharmacology 1999, 142, 334-342
12. Ross, G. W.; Petrovitch, H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease Drugs Aging 2001, 18, 797-806
13. Jorenby, D. E.; Hays, J. T.; Rigotti, N. A.; Azoulay, S.; Watsky, E. J.; Williams, K. E.; Billing, C. B.; Gong, J.; Reeves, K. R.; Bock, B.; Christen, A. G.; Gilderman, L. I.; Goldstein, S. K.; Jackson, T. C.; Make, B. J.; Merideth, C. H.; Sachs, D. P. L.; Sharp, S. C.; Swartz, S. H.; Weerasinghe, M. U. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial JAMA, J. Am. Med. Assoc. 2006, 296, 56-63
14. Paleari, L.; Cesario, A.; Fini, M.; Russo, P. α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and mesothelioma? Drug Discovery Today 2009, 14, 822-836
15. Meyer, M. D. Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain Drug Dev. Res. 2006, 67, 355-359
16. Sarter, M.; Parikh, V.; Howe, W. M. nAChR agonist-induced cognition enhancement: Integration of cognitive and neuronal mechanisms Biochem. Pharmacol. 2009, 78, 658-667
17. Dwoskin, L. P.; Smith, A. M.; Wooters, T. E.; Zhang, Z.; Crooks, P. A.; Bardo, M. T. Nicotinic receptor-based therapeutics and candidates for smoking cessation Biochem. Pharmacol. 2009, 78, 732-743
18. Holladay, M. W.; Wasicak, J. T.; Lin, N.-H.; He, Y.; Ryther, K. B.; Bannon, A. W.; Buckley, M. J.; Kim, D. J. B.; Decker, M. W.; Anderson, D. J.; Campbell, J. E.; Kuntzweiler, T. A.; Donnelly-Roberts, D. L.; Piattoni-Kaplan, M.; Briggs, C. A.; Williams, M.; Arneric, S. P. Identification and Structure-Activity Relationships of (R)-5-(2-Azetidinylmethoxy)-2-chloropyridine (ABT-594), a Potent, Orally Active, Non-Opiate Analgesic Agent Acting via Neuronal Nicotinic Acetylcholine Receptors J. Med. Chem. 1998, 41, 407-412
19. Coe, J. W.; Rollema, H.; O'Neill, B. T. Case history: Chantix/Champix (varenicline tartrate), a nicotinic acetylcholine receptor partial agonist as a smoking cessation aid Annu. Rep. Med. Chem. 2009, 44, 71-101
20. Taly, A.; Corringer, P.-J.; Guedin, D.; Lestage, P.; Changeux, J.-P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system Nature Rev. Drug Discovery 2009, 8, 733-750
21. Dani, J. A.; Bertrand, D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system Annu. Rev. Pharmacol. Toxicol. 2007, 47, 699-729
22. Sargent, P. B. The diversity of neuronal nicotinic acetylcoline receptors Annu. Rev. Neurosci. 1993, 16, 403-443
23. Lukas, R. J.; Changeux, J.-P.; Le Novere, N.; Albuquerque, E. X.; Balfour, D. J. K.; Berg, D. K.; Bertrand, D.; Chiappinelli, V. A.; Clarke, P. B. S.; Collins, A. C.; Dani, J. A.; Grady, S. R.; Kellar, K. J.; Lindstrom, J. M.; Marks, M. J.; Quik, M.; Taylor, P. W.; Wonnacott, S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits Pharmacol. Rev. 1999, 51, 397-401
24. Anderson, D. J.; Malysz, J.; Gronlien Jens, H.; El Kouhen, R.; Hakerud, M.; Wetterstrand, C.; Briggs Clark, A.; Gopalakrishnan, M. Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity α4β2 subunit combination Biochem. Pharmacol. 2009, 78, 844-851
25. Gotti, C.; Zoli, M.; Clementi, F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance Trends Pharmacol. Sci. 2006, 27, 482-491
26. Gotti, C.; Moretti, M.; Gaimarri, A.; Zanardi, A.; Clementi, F.; Zoli, M. Heterogeneity and complexity of native brain nicotinic receptors Biochem. Pharmacol. 2007, 74, 1102-1111
27. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors Biochem. Pharmacol. 2009, 78, 703-711
28. Decker, M. W.; Gopalakrishnan, M.; Meyer, M. D. The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions Expert Opin. Drug Discovery 2008, 3, 1027-1040
29. Poorthuis, R. B.; Goriounova, N. A.; Couey, J. J.; Mansvelder, H. D. Nicotinic actions on neuronal networks for cognition: General principles and long-term consequences Biochem. Pharmacol. 2009, 78, 668-676
30. Marks, M. J.; Wageman, C. R.; Grady, S. R.; Gopalakrishnan, M.; Briggs, C. A. Selectivity of ABT-089 for α4β2* and α6β 2* nicotinic acetylcholine receptors in brain Biochem. Pharmacol. 2009, 78, 910
31. Sullivan, J. P.; Bannon, A. W. Epibatidine: pharmacological properties of a novel nicotinic acetylcholine receptor agonist and analgesic agent CNS Drug Rev. 1996, 2, 21-39
32. Lin, N.-H.; Gunn, D. E.; Ryther, K. B.; Garvey, D. S.; Donnelly-Roberts, D. L.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Rodrigues, A. D.; Marsh, K G.; Anderson, D. J.; Buccafusco, J. J.; Prendergast, M. A.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Structure-Activity Studies on 2-Methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): An Orally Bioavailable 3-Pyridyl Ether Nicotinic Acetylcholine Receptor Ligand with Cognition-Enhancing Properties J. Med. Chem. 1997, 40, 385-390
33. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Xue, I. C.; Piattoni-Kaplan, M.; Molinari, E.; Campbell, J. E.; McKenna, D. G.; Gunn, D. E.; Lin, N.-H.; Ryther, K. B.; He, Y.; Holladay, M. W.; Wonnacott, S.; Williams, M.; Arneric, S. P. ABT-089 [2-methyl-3-(2-(S)- pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties J. Pharmacol. Exp. Ther. 1997, 283, 235-246
34. Decker, M. W.; Bannon, A. W.; Curzon, P.; Gunther, K. L.; Brioni, J. D.; Holladay, M. W.; Lin, N.-H.; Li, Y.; Daanen, J. F.; Buccafusco, J. J.; Prendergast, M. A.; Jackson, W. J.; Arneric, S. P. ABT-089 [2-methyl-3-(2-(S)- pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys J. Pharmacol. Exp. Ther. 1997, 283, 247-258
35. Rueter, L. E.; Anderson, D. J.; Briggs, C. A.; Donnelly-Roberts, D. L.; Gintant, G. A.; Gopalakrishnan, M.; Lin, N.-H.; Osinski, M. A.; Reinhart, G. A.; Buckley, M. J.; Martin, R. L.; McDermott, J. S.; Preusser, L. C.; Seifert, T. R.; Su, Z.; Cox, B. F.; Decker, M. W.; Sullivan, J. P. ABT-089: Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders CNS Drug Rev. 2004, 10, 167-182
36. Prendergast, M. A.; Jackson, W. J.; Terry, A. V., Jr.; Decker, M. W.; Arneric, S. P.; Buccafusco, J. J. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys Psychopharmacology 1998, 136, 50-58
37. Wilens, T. E.; Verlinden, M. H.; Adler, L. A.; Wozniak, P. J.; West, S. A. ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study Biol. Psychiatry 2006, 59, 1065-1070
38. Wilens, T. E.; Decker, M. W. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition Biochem. Pharmacol. 2007, 74, 1212-1223
39. Xiao, Y.; Fan, H.; Musachio, J. L.; Wei, Z.-L.; Chellappan, S. K.; Kozikowski, A. P.; Kellar, K. J. Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them Mol. Pharmacol. 2006, 70, 1454-1460
40. Liu, J.; Eaton, J. B.; Caldarone, B.; Lukas, R. J.; Kozikowski, A. P. Chemistry and Pharmacological Characterization of Novel Nitrogen Analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(Azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists J. Med. Chem. 2010, 53, 6973-6985
41. Bunnelle, W. H.; Tietje, K. R.; Frost, J. M.; Peters, D.; Ji, J.; Li, T.; Scanio, M. J. C.; Shi, L.; Anderson, D. J.; Dyhring, T.; Gronlien, J. H.; Ween, H.; Thorin-Hagene, K.; Meyer, M. D. Octahydropyrrolo[3,4- c ]pyrrole: a diamine scaffold for construction of either α4β2 or α7-selective nicotinic acetylcholine receptor (nAChR) ligands. substitutions that switch subtype selectivity J. Med. Chem. 2009, 52, 4126-4141
42. Schrimpf, M. R.; Tietje, K. R.; Toupence, R. B.; Ji, J.; Basha, A.; Bunnelle, W. H.; Daanen, J. F.; Pace, J. M.; Sippy, K. B. Diazabicyclic central nervous system active agents. Patent WO0181347, Nov 1, 2001.
43. Ji, J.; Schrimpf, M. R.; Sippy, K. B.; Bunnelle, W. H.; Li, T.; Anderson, D. J.; Faltynek, C.; Surowy, C. S.; Dyhring, T.; Ahring, P. K.; Meyer, M. D. Synthesis and Structure-Activity Relationship Studies of 3,6-Diazabicyclo[3.2.0] heptanes as Novel α4β2 Nicotinic Acetylcholine Receptor Selective Agonists J. Med. Chem. 2007, 50, 5493-5508
44. Carroll, F. I.; Lee, J. R.; Navarro, H. A.; Ma, W.; Brieaddy, L. E.; Abraham, P.; Damaj, M. I.; Martin, B. R. Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2-exo-2-(2′,3′- Disubstituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes: Epibatidine Analogues J. Med. Chem. 2002, 45, 4755-4761
45. Carroll, F. I.; Ware, R.; Brieaddy, L. E.; Navarro, H. A.; Damaj, M. I.; Martin, B. R. Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2′-Fluoro-3′-(substituted phenyl)deschloroepibatidine Analogues. Novel Nicotinic Antagonist J. Med. Chem. 2004, 47, 4588-4594
46. Carroll, F. I.; Brieaddy, L. E.; Navarro, H. A.; Damaj, M. I.; Martin, B. R. Synthesis and Pharmacological Characterization of exo -2-(2′-Chloro-5- pyridinyl)-7-(endo and exo)-aminobicyclo[2.2.1]heptanes as Novel Epibatidine Analogues J. Med. Chem. 2005, 48, 7491-7495
47. Frost, J. M.; Bunnelle, W. H.; Tietje, K. R.; Anderson, D. J.; Rueter, L. E.; Curzon, P.; Surowy, C. S.; Ji, J.; Daanen, J. F.; Kohlhaas, K. L.; Buckley, M. J.; Henry, R. F.; Dyhring, T.; Ahring, P. K.; Meyer, M. D. Synthesis and Structure-Activity Relationships of 3,8-Diazabicyclo[4.2.0]octane Ligands, Potent Nicotinic Acetylcholine Receptor Agonists J. Med. Chem. 2006, 49, 7843-7853
48. Schenke, T.; Petersen, U. 2,7-diazabicyclo[3.3.0]octanes and process for their formation. Eur. Patent 393424, April 4, 1990.
49. Uchimaru, F.; Okada, S.; Kosasayama, A.; Konno, T. Pyrazine derivatives. I. Synthesis of pyrazinoylmorpholine and related compounds Chem. Pharm. Bull. 1971, 19, 1337-1343
50. Okada, S.; Kosasayama, A.; Konno, T.; Uchimaru, F. Pyrazine derivatives. II. Synthesis, reactions, and spectra of pyrazine N -oxide derivatives Chem. Pharm. Bull. 1971, 19, 1344-1357
51. V1.8 sodium channel with efficacy in a model of neuropathic pain Bioorg. Med. Chem. 2010, 18, 7816-7825
52. Imai, K.-i.; Mano, M.; Seo, T.; Matsuno, T.; Anticoccidials., V. I. An improved synthesis of 1,6-dihydro-6-oxo-2-pyrazinecarboxylic acid 4-oxide and some related derivatives and determination of anticoccidial activity Chem. Pharm. Bull. 1981, 29, 88-97
53. Sato, N.; Fujii, M. Studies on pyrazines. 29. Highly regioselective synthesis of chloropyrazines from 3-substituted pyrazine 1-oxides J. Heterocycl. Chem. 1994, 31, 1177-1180
54. Guo, Z.; Dowdy, E. D.; Li, W. S.; Polniaszek, R.; Delaney, E. A novel method for the mild and selective amidation of diesters and the amidation of monoesters Tetrahedron Lett. 2001, 42, 1843-1845
55. Hartwig, J. F. Carbon-Heteroatom Bond-Forming Reductive Eliminations of Amines, Ethers, and Sulfides Acc. Chem. Res. 1998, 31, 852-860
56. Wolfe, J. P.; Wagaw, S.; Buchwald, S. L. An Improved Catalyst System for Aromatic Carbon-Nitrogen Bond Formation: The Possible Involvement of Bis(Phosphine) Palladium Complexes as Key Intermediates J. Am. Chem. Soc. 1996, 118, 7215-7216
57. 3H] methylcarbamylcholine in rat brain Eur. J. Pharmacol. 1994, 253, 261-267
58. 3H]A-585539 [(1 S,4 S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1] heptane], a novel high-affinity α7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain J. Pharmacol. Exp. Ther. 2008, 324, 179-187
59. Kuntzweiler, T. A.; Arneric, S. P.; Donnelly-Roberts, D. L. Rapid assessment of ligand actions with nicotinic acetylcholine receptors using calcium dynamics and FLIPR Drug Dev. Res. 1998, 44, 14-20
60. Gronlien, J. H.; Hakerud, M.; Ween, H.; Thorin-Hagene, K.; Briggs Clark, A.; Gopalakrishnan, M.; Malysz, J. Distinct profiles of α7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes Mol. Pharmacol. 2007, 72, 715-724
61. Glennon, R. A.; Dukat, M. α4β2 nACh Receptor pharmacophore models Bioorg. Med. Chem. Lett. 2004, 14, 1841-1844
62. Tonder, J. E.; Olesen, P. H. Agonists at the α4β2 nicotinic acetylcholine receptors: structure-activity relationships and molecular modeling Curr. Med. Chem. 2001, 8, 651-674
63. Zhong, W.; Gallivan, J. P.; Zhang, Y.; Li, L.; Lester, H. A.; Dougherty, D. A. From ab initio quantum mechanics to molecular neurobiology: a cation-π binding site in the nicotinic receptor Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12088-12093
64. 3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine Biochemistry 2002, 41, 10262-10269
65. Xiu, X.; Puskar, N. L.; Shanata, J. A. P.; Lester, H. A.; Dougherty, D. A. Nicotine binding to brain receptors requires a strong cation-π interaction Nature 2009, 458, 534-537
66. Toma, L.; Quadrelli, P.; Bunnelle, W. H.; Anderson, D. J.; Meyer, M. D.; Cignarella, G.; Gelain, A.; Barlocco, D. 6-Chloropyridazin-3-yl Derivatives Active as Nicotinic Agents: Synthesis, Binding, and Modeling Studies J. Med. Chem. 2002, 45, 4011-4017
67. Dukat, M.; Dowd, M.; Damaj, M. I.; Martin, B.; El-Zahabi, M. A.; Glennon, R. A. Synthesis, receptor binding and QSAR studies on 6-substituted nicotine derivatives as cholinergic ligands Eur. J. Med. Chem. 1999, 34, 31-40
68. Briggs, C. A.; Gubbins, E. J.; Marks, M. J.; Putman, C. B.; Thimmapaya, R.; Meyer, M. D.; Surowy, C. S. Untranslated region-dependent exclusive expression of high-sensitivity subforms of α4β2 and α3β2 nicotinic acetylcholine receptors Mol. Pharmacol. 2006, 70, 227-240
69. Coe, J. W.; Brooks, P. R.; Vetelino, M. G.; Wirtz, M. C.; Arnold, E. P.; Huang, J.; Sands, S. B.; Davis, T. I.; Lebel, L. A.; Fox, C. B.; Shrikhande, A.; Heym, J. H.; Schaeffer, E.; Rollema, H.; Lu, Y.; Mansbach, R. S.; Chambers, L. K.; Rovetti, C. C.; Schulz, D. W.; Tingley, F. D.; O'Neill, B. T. Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation J. Med. Chem. 2005, 48, 3474-3477
70. Cohen, C.; Bergis, O. E.; Galli, F.; Lochead, A. W.; Jegham, S.; Biton, B.; Leonardon, J.; Avenet, P.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Voltz, C.; Gardes, A.; Caille, D.; Perrault, G.; George, P.; Soubrie, P.; Scatton, B. SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential as an aid to smoking cessation J. Pharmacol. Exp. 2003, 306, 407-420
71. Lippiello, P.; Letchworth, S. R.; Gatto, G. J.; Traina, V. M.; Bencherif, M. Ispronicline: a novel α4β2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties J. Mol. Neurosci. 2006, 30, 19-20
72. Mihalak, K. B.; Carroll, I.; Luetje, C. W. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors Mol. Pharmacol. 2006, 70, 801-805